Quick Answer
Ultragenyx Pharmaceutical Inc. reported Diluted EPS of $5.83 per share (loss) for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.83 | +7.3% |
| 2024 | -$6.29 | +23.8% |
| 2023 | -$8.25 | +18.5% |
| 2022 | -$10.12 | -51.0% |
| 2021 | -$6.70 | -118.2% |
| 2020 | -$3.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.81 | -29.3% | -54.7% |
| June 30, 2025 | -$1.17 | +23.0% | +25.5% |
| March 31, 2025 | -$1.57 | +22.7% | -12.1% |
| September 30, 2024 | -$1.40 | +37.2% | +7.9% |
| June 30, 2024 | -$1.52 | +32.4% | +25.1% |
| March 31, 2024 | -$2.03 | +12.9% | +9.0% |
| September 30, 2023 | -$2.23 | +36.3% | +0.9% |
| June 30, 2023 | -$2.25 | +0.4% | +3.4% |
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Ultragenyx Pharmaceutical Inc.’s diluted eps has declined by 89.9% (from $3.07 per share (loss) to $5.83 per share (loss)).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: